Phenylephrine

KVUE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action Commenced by the Firm – KVUE

Retrieved on: 
Tuesday, December 5, 2023
Titan, Phenylephrine, Court, Register, KVUE, Advertising, Prospectus, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

DEADLINE ALERT for AAP, KVUE, CGRN, NKLA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, December 5, 2023
Telephone, Suite, Risk, Phenylephrine, Class, Law, Bank statement, Perception, Investment, Safety, Security (finance)

BENSALEM, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

KVUE 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kenvue, Inc. (KVUE) Investors with Substantial Losses to Contact its Attorneys Before Dec. 8th Deadline in Securities Class Action

Retrieved on: 
Monday, December 4, 2023
Risk, Phenylephrine, FDA, Hagens Berman, SAN, KVUE, Person, IPO, Pharmaceutical industry

On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.

Key Points: 
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .

KVUE Shareholder Update: Johnson Fistel Encourages Kenvue Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline

Retrieved on: 
Monday, December 4, 2023
LLP, Action Replay, Court, Risk, SAN, Complaint, Phenylephrine, KVUE

SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP notifies investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) a securities class action lawsuit has been filed.

Key Points: 
  • SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP notifies investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) a securities class action lawsuit has been filed.
  • Investors have until December 8, 2023, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit.
  • An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on: 
Monday, December 4, 2023
Nasal, Food, Risk, Johnson & Johnson, CFR, Phenylephrine, Petition, J&J, LLP, FDA, Ext, Court, Initiative, Find, Person, Nasal congestion, Register, News, Complaint, Pomerantz, KVUE, Prior, Prospectus, Safety, Defendant, District court, Action Replay, Pharmaceutical industry

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

DEADLINE ALERT for GCT, DLO, AAP, and KVUE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, December 4, 2023
Suite, DLocal, Risk, Phenylephrine, Disclosure, Register, Law, Perception, Investment, Defendant, Security (finance)

LOS ANGELES, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

KENVUE SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kenvue To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, December 2, 2023
Risk, Johnson & Johnson, Phenylephrine, LLP, FDA, Court, Complaint, KVUE, Advertising, Prospectus, Defendant, Woman, Security (finance)

NEW YORK, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and reminds investors of the December 8, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Kenvue’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

KVUE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action Commenced by the Firm – KVUE

Retrieved on: 
Saturday, December 2, 2023
Titan, Phenylephrine, Court, Register, KVUE, Advertising, Prospectus, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kenvue, Inc. (KVUE) Investors with Substantial Losses to Contact its Attorneys Before Dec. 8th Deadline in Securities Fraud Class Action

Retrieved on: 
Friday, December 1, 2023
Risk, Phenylephrine, FDA, Hagens Berman, SAN, KVUE, Person, IPO, Pharmaceutical industry

On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.

Key Points: 
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .

KENVUE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kenvue Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 1, 2023
Telephone, Risk, Phenylephrine, Person, Court, Register, P.C, KVUE, IPO, Prospectus, District court

Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • If you purchased or otherwise acquired Kenvue shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.